{"title":"<i>Cannabis</i>: Drug of Abuse and Therapeutic Agent, Two Sides of the Same Coin.","authors":"Ana Canseco-Alba, Gabriela Rodríguez-Manzo","doi":"10.24875/RIC.23000112","DOIUrl":null,"url":null,"abstract":"<p><p>The consumption of <i>Cannabis sativa</i> plant, known as marijuana in the Western world, for different purposes (therapeutic, intoxicating, and spiritual) due to its psychoactive effects, can be traced back to ancient times. <i>Cannabis</i> is the most used illicit drug worldwide; however, its legal status is changing rapidly. <i>Cannabis</i> regulation will allow a better understanding of its effects as a misused drug, including new challenges, such as the availability of highly potent <i>Cannabis extracts</i>. Furthermore, scientific research is making significant efforts to take advantage of the potential therapeutic uses of <i>Cannabis</i> active compounds. The science of <i>Cannabis</i> derivatives started with the identification of the phytocannabinoids Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC) and cannabidiol (CBD), allowing the formal study of the complex set of effects triggered by <i>Cannabis</i> consumption and the deciphering of its pharmacology. Δ<sup>9</sup>-THC is recognized as the compound responsible for the psychoactive and intoxicating effects of <i>Cannabis</i>. Its study led to the discovery of the endocannabinoid system, a neuromodulatory system widespread in the human body. CBD does not induce intoxication and for that reason, it is the focus of the search for cannabinoid potential clinical applications. This review examines the current state of knowledge about contrasting perspectives on the effects of <i>Cannabis</i>, Δ<sup>9</sup>-THC, and CBD: their abuse liability and potential therapeutic use; two sides of the same coin.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"75 3","pages":"105-128"},"PeriodicalIF":1.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista De Investigacion Clinica-Clinical and Translational Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/RIC.23000112","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The consumption of Cannabis sativa plant, known as marijuana in the Western world, for different purposes (therapeutic, intoxicating, and spiritual) due to its psychoactive effects, can be traced back to ancient times. Cannabis is the most used illicit drug worldwide; however, its legal status is changing rapidly. Cannabis regulation will allow a better understanding of its effects as a misused drug, including new challenges, such as the availability of highly potent Cannabis extracts. Furthermore, scientific research is making significant efforts to take advantage of the potential therapeutic uses of Cannabis active compounds. The science of Cannabis derivatives started with the identification of the phytocannabinoids Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), allowing the formal study of the complex set of effects triggered by Cannabis consumption and the deciphering of its pharmacology. Δ9-THC is recognized as the compound responsible for the psychoactive and intoxicating effects of Cannabis. Its study led to the discovery of the endocannabinoid system, a neuromodulatory system widespread in the human body. CBD does not induce intoxication and for that reason, it is the focus of the search for cannabinoid potential clinical applications. This review examines the current state of knowledge about contrasting perspectives on the effects of Cannabis, Δ9-THC, and CBD: their abuse liability and potential therapeutic use; two sides of the same coin.
期刊介绍:
The Revista de Investigación Clínica – Clinical and Translational Investigation (RIC-C&TI), publishes original clinical and biomedical research of interest to physicians in internal medicine, surgery, and any of their specialties. The Revista de Investigación Clínica – Clinical and Translational Investigation is the official journal of the National Institutes of Health of Mexico, which comprises a group of Institutes and High Specialty Hospitals belonging to the Ministery of Health. The journal is published both on-line and in printed version, appears bimonthly and publishes peer-reviewed original research articles as well as brief and in-depth reviews. All articles published are open access and can be immediately and permanently free for everyone to read and download. The journal accepts clinical and molecular research articles, short reports and reviews.
Types of manuscripts:
– Brief Communications
– Research Letters
– Original Articles
– Brief Reviews
– In-depth Reviews
– Perspectives
– Letters to the Editor